Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 20 2023 - 5:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April
2023
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
England and Wales
(Jurisdiction
of Incorporation)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press Release entitled 2023 AGM trading update dated
April
20, 2023
|
2023 AGM trading update
20 April 2023: Haleon plc
(the "Company") (LSE/NYSE: HLN) today provides the following update
ahead of the Annual General Meeting (AGM).
Trading in the first quarter of 2023 has been strong with organic
revenue growth of 9.9%, with price +7.1%, and also volume mix +2.8%
despite annualising the impact of the prior year ERP system cutover
and distribution business model change which increased Q1
2022 sales by c.£50m.
Growth was seen across Respiratory Health, Pain Relief, Oral Health
and Digestive Health and Other. Respiratory Health revenue was
particularly strong given a continued strong cold and flu season,
as well as some re-stocking in EMEA and LatAm, and North America
given the particularly low inventory levels at the end of last
year. In VMS revenue declined largely due to the strong comparative
for Emergen-C in the US during the Omicron wave in Q1
2022. Centrum was up high single
digit.
By geography performance was strong, with double digit growth in
both EMEA and LatAm, and Asia Pacific, and mid-single digit growth
in North America. Asia Pacific was boosted by strength in China,
particularly in Pain Relief as lockdowns ended, combined with
elevated COVID-19 and cold and flu incidence. Performance in North
America was impacted by the decline in Emergen-C which partly offset very good growth in
Respiratory Health and Pain Relief.
As a result of the strong start to the year, FY 2023 organic
revenue growth is now expected to be towards the upper end of the
4-6% guidance range as provided with the FY 2022
results1.
All other FY 2023 guidance remains unchanged.
The Group will provide a full update with its first quarter trading
statement on 3 May 2023.
Revenue by product category for the three months ended 31
March:
|
|
Revenue (£m)
|
|
|
|
|
|
2023
|
2022
|
|
Reported
|
Organic2
|
|
|
Oral Health
|
811
|
741
|
|
9.4%
|
6.6%
|
|
|
VMS
|
405
|
405
|
|
0%
|
(3.7)%
|
|
|
Pain Relief
|
724
|
635
|
|
14.0%
|
11.0%
|
|
|
Respiratory Health
|
510
|
367
|
|
39.0%
|
33.0%
|
|
|
Digestive Health and Other
|
536
|
479
|
|
11.9%
|
7.3%
|
|
|
Group revenue
|
2,986
|
2,627
|
|
13.7%
|
9.9%
|
|
|
|
|
|
|
|
|
|
|
Revenue by geographical segment for the three months ended 31
March:
|
|
Revenue (£m)
|
|
|
|
|
2023
|
2022
|
|
Reported
|
Organic2
|
|
Price2
|
Vol/Mix2
|
|
North America
|
1,072
|
940
|
|
14.0%
|
5.1%
|
|
3.6%
|
1.5%
|
|
EMEA and LatAm
|
1,198
|
1,057
|
|
13.3%
|
13.1%
|
|
12.6%
|
0.5%
|
|
APAC
|
716
|
630
|
|
13.7%
|
11.7%
|
|
3.4%
|
8.3%
|
|
Group
|
2,986
|
2,627
|
|
13.7%
|
9.9%
|
|
7.1%
|
2.8%
|
1 Please
note that we are unable to present a reconciliation of
forward-looking information for organic revenue growth because we
are unable to forecast accurately certain adjusting items required
to present a meaningful comparable IFRS forward looking financial
measure.
2 Definitions
of non-IFRS measures can be found on pages 23-31 of the 2022 Full
year results, and pages 36-55 in Haleon's Annual Report and Form
20-F.
Enquiries
|
Investors
|
Media
|
|
Sonya Ghobrial
|
+44 7392 784784
|
Zoe Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Nidaa Lone
|
+44 7841 400607
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon plc
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
Cautionary note regarding forward-looking statements
This document contains certain statements that are, or may be
deemed to be, "forward-looking statements" (including for purposes
of the safe harbor provisions for forward-looking statements
contained in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934). Forward-looking
statements give Haleon's current expectations and projections about
future events, including strategic initiatives and future financial
condition and performance, and so Haleon's actual results may
differ materially from what is expressed or implied by such
forward-looking statements. All statements, other than statements
of historical facts, included in this presentation are
forward-looking statements. Such forward-looking statements include
statements relating to future performance and financial
results.
Any forward-looking statements made by or on behalf of Haleon speak
only as of the date they are made and are based upon the knowledge
and information available to Haleon on the date of this document.
These forward-looking statements and views may be based on a number
of assumptions and, by their nature, involve known and unknown
risks, uncertainties and other factors because they relate to
events and depend on circumstances that may or may not occur in the
future and/or are beyond Haleon's control or precise estimate. Such
risks, uncertainties and other factors that could cause Haleon's
actual results, performance or achievements to differ materially
from those in the forward-looking statements include, but are not
limited to, those discussed under "Risk Factors" on pages 202 to
210 in Haleon's Annual Report and Form 20-F 2022. Forward-looking
statements should, therefore, be construed in light of such risk
factors and undue reliance should not be placed on forward-looking
statements.
Subject to our obligations under English and U.S. law in relation
to disclosure and ongoing information (including under the Market
Abuse Regulations, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority ("FCA")), we
undertake no obligation to update publicly or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. You should, however, consult any
additional disclosures that Haleon may make in any documents which
it publishes and/or files with the SEC and take note of these
disclosures, wherever you are located.
No statement in this document is or is intended to be a profit
forecast or profit estimate.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON
PLC
(Registrant)
|
|
Dated: April 20,
2023
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Haleon (NYSE:HLN)
Historical Stock Chart
From Jan 2024 to Jan 2025
